Drug intelligence / Profile preview

NCE-052

Development stage: Preclinical
Modality: Small Molecules

Overview

NCE-052 is a novel small molecule positive allosteric modulator (PAM) of the Kv3.1 (KCNC1) voltage-gated potassium channel. It is being developed for the treatment of epilepsy and seizure control, specifically targeting the restoration of rapid parvalbumin-positive interneuron (PVI) firing. In preclinical studies using *Scn1a* haploinsufficient mouse models, NCE-052 has demonstrated the ability to delay seizure onset and significantly increase the temperature threshold for febrile seizures. It was designed as an analog of existing Kv3.1 modulators to improve upon the properties of tool compounds like AUT1, aiming for potential human therapeutic use in seizure suppression and epilepsy prevention.

Targets

KCNC1 (Kv3.1)

Beyond the preview

Go deeper on NCE-052.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCE-052.

Explore the full profile